

Application No.: 09/782,587
Attorney Docket No: 0212us310
Page 2 of 10

Listing of Claims:

The following listing of claims replaces all prior versions and listings of claims in the application, in accordance with the revised amendment format as set forth in 1267 OG 106 (February 25, 2003).

1. - 67. (Cancelled)

68. (New) A conjugate comprising:

A/
a polypeptide comprising an amino acid sequence which (a) differs from the hFVII or hFVIIa sequence SEQ ID NO:1 in 1-15 amino acid residues and (b) comprises an introduced *in vivo* N-glycosylation site relative to SEQ ID NO:1, wherein the introduced *in vivo* N-glycosylation site comprises a substitution selected from the group consisting of T106N, I205S/T, V253N, T267N, and R315N+V317S/T; and

a sugar moiety covalently attached to the introduced *in vivo* N-glycosylation site.

69. (New) The conjugate of claim 68, comprising two or more said introduced *in vivo* N-glycosylation sites.

70. (New) The conjugate of claim 68, comprising the substitution T106N.

71. (New) The conjugate of claim 68, comprising the substitution I205S/T.

72. (New) The conjugate of claim 68, comprising the substitution V253N.

73. (New) The conjugate of claim 68, comprising the substitution T267N.

74. (New) The conjugate of claim 68, comprising the substitution R315N+V317S/T.

Cont
AI

Application No.: 09/782,587
Attorney Docket No: 0212us310
Page 3 of 10

75. (New) The conjugate of claim 69, comprising the substitutions T106N and I205S/T.
76. (New) The conjugate of claim 69, comprising the substitutions T106N and V253N.
77. (New) The conjugate of claim 69, comprising the substitutions T106N and R315N+V317S/T.
78. (New) The conjugate of claim 69, comprising the substitutions I205S/T and T267N.
79. (New) The conjugate of claim 69, comprising the substitutions I205S/T and V253N.
80. (New) The conjugate of claim 69, comprising the substitutions V253N and T267N.
81. (New) The conjugate of claim 69, comprising the substitutions T106N, I205S/T, and V253N.
82. (New) The conjugate of claim 69, comprising the substitutions T106N, I205S/T, and T267N.
83. (New) The conjugate of claim 69, comprising the substitutions T106N, V253N, and T267N.
84. (New) The conjugate of claim 69, comprising the substitutions I205S/T, V253N, and T267N.
85. (New) The conjugate of claim 68, further comprising at least one additional introduced *in vivo* N-glycosylation site.
86. (New) The conjugate of claim 85, wherein the additional introduced *in vivo* N-glycosylation site is introduced in a position relative to SEQ ID NO:1 occupied by an amino acid residue with more than 25% of its side chain exposed to the solvent.

Cont
AI

Application No.: 09/782,587
Attorney Docket No: 0212us310
Page 4 of 10

87. (New) The conjugate of claim 85, wherein the additional introduced *in vivo* N-glycosylation site comprises an amino acid substitution in a position selected from the group consisting of 28-48, 139-147, 286-294, 311-319, 338-345 and 388-406 relative to SEQ ID NO:1.

88. (New) The conjugate of claim 68, further comprising at least one non-polypeptide moiety covalently attached to an amino acid residue of the polypeptide, wherein the non-polypeptide moiety is different from a sugar moiety.

89. (New) The conjugate of claim 88, wherein the non-polypeptide moiety is a polymer molecule.

90. (New) The conjugate of claim 82, wherein the polymer molecule is a linear polyethylene glycol or a branched polyethylene glycol.

91. (New) The conjugate of claim 68, exhibiting at least 10% of the catalytic activity of hFVIIa.

92. (New) The conjugate of claim 68, exhibiting at least 25% of the clotting activity of hFVIIa.

93. (New) A polypeptide comprising the amino acid sequence of claim 68.

94. (New) The polypeptide of claim 93, exhibiting at least 10% of the catalytic activity of hFVIIa.

95. (New) The polypeptide of claim 93, exhibiting at least 25% of the clotting activity of hFVIIa.

96. (New) A nucleotide sequence encoding the polypeptide of claim 93.

97. (New) An expression vector comprising the nucleotide sequence of claim 96.

Cont
A1

Application No.: 09/782,587
Attorney Docket No: 0212us310
Page 5 of 10

98. (New) A host cell comprising the nucleotide sequence of claim 96.
99. (New) The host cell of claim 98, which is a glycosylating host cell.
100. (New) The glycosylating host cell of claim 99, which is a fungal cell, an insect cell, or a mammalian cell.
101. (New) The glycosylating host cell of claim 100, which is a mammalian cell selected from a CHO cell, a BHK cell, and an HEK cell.
102. (New) The glycosylating host cell of claim 100, which is a fungal cell selected from an *S. cerevisiae* cell and a *Pichia pastoris* cell.
-
103. (New) A composition comprising the conjugate of claim 68 and a pharmaceutically acceptable carrier or excipient.
104. (New) The composition of claim 103, wherein the composition is an aqueous solution.
105. (New) The composition of claim 103, comprising a buffering agent.
-
106. (New) A method for increasing blood clot formation in a mammal with a disease or condition in which increased clot formation is desirable, comprising administering to the mammal an amount of the conjugate of claim 68 effective to increase blood clot formation.
107. (New) The method of claim 106, wherein the disease or condition is associated with severe tissue damage.
108. (New) The method of claim 106 wherein the disease or condition is associated with trauma.

Ant
A1

Application No.: 09/782,587
Attorney Docket No: 0212us310
Page 6 of 10

109. (New) The method of claim 106, wherein the disease or condition is associated with major surgery.

110. (New) The method of claim 106, wherein the disease or condition is hemophilia or thrombocytopenia.

111. (New) A method for preparing a composition, comprising mixing the conjugate of claim 68 with a pharmaceutically acceptable carrier or excipient.

112. (New) The method of claim 111, wherein the pharmaceutically acceptable excipient comprises a buffering agent.

113. (New) A method for producing a conjugate, the method comprising:
providing a culture comprising a glycosylating host cell, the glycosylating host cell comprising an expression vector comprising a nucleotide sequence which encodes the polypeptide of claim 93, culturing the culture under conditions which permit expression and glycosylation of the polypeptide, and recovering the resulting conjugate.

114. (New) The method of claim 113, wherein the glycosylating host cell is a fungal cell, an insect cell, or a mammalian cell.

115. (New) The method of claim 114, wherein the glycosylating host cell is a mammalian cell selected from a CHO cell, a BHK cell, and an HEK cell.

116. (New) The method of claim 114, wherein the glycosylating host cell is a fungal cell selected from an *S. cerevisiae* cell and a *Pichia pastoris* cell.